BackInsulet Overview
Insulet Corporation

Insulet Target Price

Analysts' average 12-month price target for Insulet is $230.

Get informed when a big investor buys or sells

+ Follow

Share Price

$166.82

Average Target Price

$229.6737.7% upside

24 analysts in the last 4 months

High: $325 | Low: $174

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-28UBS$1744.3% upsideOpen
2026-07-13Truist Financial$21025.9% upsideOpen
2026-07-13RBC Capital$24546.9% upsideOpen
2026-07-10Stifel Nicolaus$22534.9% upsideOpen
2026-07-06Evercore ISI$1807.9% upsideOpen
2026-06-23Deutsche Bank$19013.9% upsideOpen
2026-06-11UBS$21931.3% upsideOpen
2026-06-11Truist FinancialRichard Newitter$21931.3% upsideOpen
2026-06-08Raymond James$21629.5% upsideOpen
2026-05-27Goldman SachsDavid Roman$20522.9% upsideOpen
2026-05-26BTIG$23540.9% upsideOpen
2026-05-07Goldman Sachs$23742.1% upsideOpen
2026-05-07RBC CapitalShagun Singh$28067.8% upsideOpen
2026-05-07Truist FinancialRichard Newitter$25049.9% upsideOpen
2026-05-07Evercore ISI$20019.9% upsideOpen
2026-05-07Oppenheimer$21025.9% upsideOpen
2026-05-07Stifel Nicolaus$25049.9% upsideOpen
2026-05-07Canaccord GenuityWilliam Plovanic$24949.3% upsideOpen
2026-05-07Bernstein$20019.9% upsideOpen
2026-05-07BarclaysMatt Miksic$19818.7% upsideOpen
2026-05-06BTIG$26055.9% upsideOpen
2026-04-24Redburn Partners$22031.9% upsideOpen
2026-04-15Truist FinancialRichard Newitter$31588.8% upsideOpen
2026-04-14RBC CapitalShagun Singh$32594.8% upsideOpen
2026-02-19Truist Financial$360115.8% upsideOpen
2026-02-19Evercore ISI$340103.8% upsideOpen
2026-02-19Goldman SachsDavid Roman$32695.4% upsideOpen
2026-02-19Oppenheimer$30079.8% upsideOpen
2026-02-19Bernstein$33097.8% upsideOpen
2026-02-19Barclays$28671.4% upsideOpen
2026-02-18Canaccord GenuityWilliam Plovanic$435160.8% upsideOpen
2026-02-04Stifel Nicolaus$350109.8% upsideOpen
2026-01-12Barclays$27464.2% upsideOpen
2026-01-09BernsteinLee Hambright$380127.8% upsideOpen
2026-01-09Goldman SachsDavid Roman$365118.8% upsideOpen
2025-12-18Truist Financial$390133.8% upsideOpen
2025-12-17Canaccord Genuity$450169.8% upsideOpen
2025-12-16Evercore ISI$370121.8% upsideOpen
2025-11-24Canaccord Genuity$432159% upsideOpen
2025-11-21Truist FinancialRichard Newitter$412147% upsideOpen
2025-11-21RBC CapitalShagun Singh$380127.8% upsideOpen
2025-11-21BTIG$380127.8% upsideOpen
2025-11-19UBS$400139.8% upsideOpen
2025-11-06JefferiesMatthew Taylor$400139.8% upsideOpen
2025-11-06BTIGMarie Thibault$370121.8% upsideOpen
2025-11-05BarclaysMatt Miksic$30180.4% upsideOpen
2025-10-10RBC Capital$365118.8% upsideOpen
2025-09-29Canaccord Genuity$399139.2% upsideOpen
2025-04-28Wells Fargo$32293% upsideOpen
2024-11-08BTIGMarie Thibault$27061.9% upsideOpen

Insulet (PODD) FAQ

The latest target price for PODD is $230. Investors often review this figure alongside Insulet's historical trend and sector peers before judging valuation or financial health.

Insulet trades near $166.82 while the consensus target sits at $230 (37.7% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting PODD's target price ($230), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Insulet's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.